Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2018
Effectiveness of second-dose varicella vaccination as post-exposure prophylaxis: a prospective cohort study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wu Q, Liu J, Wang Y, Zhou Q, Wang X, Xuan Z, Zhang L, Gao Y, Chen B, Hu Y
Аннотация
OBJECTIVES: Although administration of a second dose of varicella vaccine (2nd-dose VarV) to individuals who have previously received one-dose VarV has been recommended as a post-exposure prophylaxis (PEP) strategy for outbreak control, the effectiveness of this strategy remains unclear. We evaluated the vaccine effectiveness (VE) of 2nd-dose VarV as PEP among students involved in 129 varicella outbreaks in Shanghai, China from 2013 to 2016.
METHODS: Students who had received one-dose VarV more than 5 years prior to varicella exposure were eligible to receive 2nd-dose VarV as PEP. We evaluated the VE using the following formula: VE = (1 - hazard ratio (HR)) × 100%.
RESULTS: A total of 6762 students were eligible for 2nd-dose VarV, of whom 58.6% accepted PEP after varicella exposure. The adjusted VE of 2nd-dose VarV as PEP was 77% (95% confidence interval 64-85%). In addition, the adjusted VE of 2nd-dose VarV as PEP in affected classrooms with high vaccine uptake was higher than that in classrooms with lower vaccine uptake (87% vs. 69%). The adjusted VE was also higher in students who received 2nd-dose VarV within 3 days of exposure than those who received it more than 3 days post exposure (77% vs. 64%).
CONCLUSIONS: These Results suggest that administration of 2nd-dose VarV as PEP is an appropriate intervention for outbreak control in countries where two-dose VarV has not been adopted.
METHODS: Students who had received one-dose VarV more than 5 years prior to varicella exposure were eligible to receive 2nd-dose VarV as PEP. We evaluated the VE using the following formula: VE = (1 - hazard ratio (HR)) × 100%.
RESULTS: A total of 6762 students were eligible for 2nd-dose VarV, of whom 58.6% accepted PEP after varicella exposure. The adjusted VE of 2nd-dose VarV as PEP was 77% (95% confidence interval 64-85%). In addition, the adjusted VE of 2nd-dose VarV as PEP in affected classrooms with high vaccine uptake was higher than that in classrooms with lower vaccine uptake (87% vs. 69%). The adjusted VE was also higher in students who received 2nd-dose VarV within 3 days of exposure than those who received it more than 3 days post exposure (77% vs. 64%).
CONCLUSIONS: These Results suggest that administration of 2nd-dose VarV as PEP is an appropriate intervention for outbreak control in countries where two-dose VarV has not been adopted.